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Sustained monomorphic ventricular tachycardia (VT) is
most commonly due to reentry in a region of prior myocar-
dial infarction or ventricular scar. It may be hemodynami-
cally tolerated, or if rapid, produce hemodynamic collapse
with syncope or cardiac arrest. The vast majority of cases are
paroxysmal. Following termination of tachycardia by cardio-
version or antiarrhythmic drug administration, stable sinus
rhythm returns and persists. Recurrences are common, how-
ever, with more than a 20% of patients experiencing another
episode within two years, even if antiarrhythmic drug therapy
is utilized (1,2). An implantable cardioverter-defibrillator
(ICD) is an excellent option for many patients, providing
effective termination of the arrhythmia, often with a burst of
antitachycardia pacing, or failing that, a shock.
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Ventricular tachycardia that repeatedly recurs and persists
for more than half of a 24-h period despite repeated attempts
to terminate the arrhythmia is designated “incessant.” Depend-
ing on the rate and associated heart disease, the clinical
consequence ranges from asymptomatic elevation in heart rate
to death. Rarely, idiopathic VT that is not associated with
structural heart disease is incessant (3). The most common type
originates from the right ventricular outflow tract, causing a left
bundle branch block, inferior axis configuration VT. It may be
relatively slow and asymptomatic, or cause palpitations or
symptoms of hypotension. Incessant idiopathic VT can cause
tachycardia-induced cardiomyopathy if not recognized and
treated (4). More commonly, incessant VT is due to structural
heart disease, with severe, immediate consequences.
Incessant VT typically takes one of two forms. The most
common situation is for VT to be sustained, terminated by
external cardioversions, but recurrent. The time between
cardioversion and recurrence may be seconds, minutes or
more. A second form, common with the idiopathic VTs,
manifests as repeated bursts, with runs of VT that sponta-
neously terminate for a few intervening sinus beats, followed
by the next tachycardia burst (3). Cardioversion is futile, but
may be periodically required if bursts of VT occasionally
degenerate to ventricular fibrillation.
Often incessant VT evolves from an episode of mono-
morphic VT. Following termination of an episode of VT,
an antiarrhythmic drug, commonly intravenous amioda-
rone, may be administered (5). Repeated episodes of VT
after antiarrhythmic drug administration may simply indi-
cate that the drug is ineffective. It is important, however, to
recognize the possibility of a drug induced proarrhythmic
effect, which may take the form of slowing the VT, but
rendering it incessant. Such proarrhythmia was well recog-
nized during therapy with antiarrhythmic drugs that prom-
inently slowed conduction velocity, such as flecainide,
propafenone, and moricizine (6,7). Treatment is directed at
maintaining hemodynamic support until the drug is ex-
creted. This type of proarrhythmia may respond favorably to
a beta-adrenergic blocking agent or lidocaine (7). In general
administration of additional antiarrhythmic drugs should be
avoided, however, because they may exacerbate the arrhyth-
mia or hemodynamic tolerance of the tachycardia.
When incessant VT is polymorphic, drug induced torsade
de pointes associated with QT prolongation, or myocardial
ischemia are the major concerns (8). Runs of polymorphic
VT may even repeatedly initiate monomorphic VT in
patients with reentry circuits in regions of scar. Suppression
of torsade de pointes with intravenous administration of
magnesium sulfate and/or overdrive pacing may restore
stability. Coronary angiography and intervention for an
acute ischemic syndrome may be required.
Sedation and measures to reduce sympathetic tone are
important, and often effective (9). If episodes of arrhythmia
are not precipitated by slow heart rates or pauses, adminis-
tration of beta-adrenergic blockers should be considered.
General anesthesia quiets episodes and restores stability in
some cases. Intra-aortic balloon counter-pulsation can also
be helpful (10). When incessant VT associated with struc-
tural heart disease is not due to a reversible cause or when
hemodynamic stability cannot be maintained such that the
underlying cause can be treated, the outcome is often death.
Catheter ablation is an important option for management
of incessant monomorphic VT and can be life-saving
(11,12). When hemodynamic stability can be maintained,
presence of the tachycardia facilitates mapping to identify
the source of the arrhythmia. Ablation typically terminates
the arrhythmia, restoring hemodynamic stability. Most scar
related reentry circuits in patients with prior myocardial infarc-
tion are located on the endocardium and are susceptible to
catheter ablation from an intravascular, endocardial approach
(13). However, 10% to 20% of patients have reentry circuits
that are not successfully ablated. The location of some circuits
deep to the endocardium or in the epicardium, are important
causes for failure. For patients with incessant VT, remaining
options then include arrhythmia surgery, placement of a
ventricular assist device, or cardiac transplantation (14).
In 1996, Sosa et al. (15) reported a percutaneous catheter
technique for mapping the epicardium from the pericardial
space in patients with ventricular tachycardia due to Chagas
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disease. They subsequently demonstrated, consistent with
observations made during surgery by Svenson and coworkers,
that some VTs due to prior inferior wall infarction can be
ablated with this epicardial approach (16,17).
In this issue of the Journal, Brugada et al. (18) report their
experience with epicardial catheter ablation for incessant
VT. Of all patients undergoing ablation at their center, 19,
approximately 7%, had incessant VT. An epicardial ap-
proach was attempted in 10 patients, either because endo-
cardial ablation failed or endocardial mapping was pre-
cluded by presence of left ventricular thrombus or peripheral
vascular disease. Incessant VT was successfully ablated from
the epicardium in 8 of 10 patients.
Several caveats should be noted. Catheter ablation of scar
related VT remains more challenging than ablation of
supraventricular tachycardias, and experience outside of
large, experienced centers is limited. Safety in the small
reported series of epicardial catheter ablation has been quite
good. Hemopericardium requiring drainage has occurred.
Transient pain consistent with pericarditis after the proce-
dure is not uncommon. Damage to epicardial coronary arteries,
the left phrenic nerve, and adjacent lung are potential concerns
that warrant careful consideration during the procedure. Cor-
onary angiography to assess proximity to large epicardial vessels
is usually performed. In some patients pericardial fibrosis from
prior cardiac surgery may prevent percutaneous access to the
pericardial space. A surgical approach to the epicardium may
be a reasonable consideration for some of these patients, when
expertise in arrhythmia surgery is available.
Questions remain regarding management after ablation.
The majority of patients with scar-related VTs have more
than one potential reentry circuit and many morphologies of
monomorphic VT inducible with electrophysiologic testing
(12). After ablation of incessant VT, ablation of other VTs
is often considered. The long-term follow-up after ablation
is still being defined. In series where ablation targets are
stable, “mapable VTs” after myocardial infarction, more
than 20% of patients experience a recurrence after initially
successful ablation (12,19). Whether recurrences will be
diminished with more extensive ablation approaches target-
ing regions of scar, remains to be assessed during long-term
follow-up (13). Although most recurrences are not fatal, the
excellent efficacy of ICDs for terminating recurrences with
antitachycardia pacing and the potential for avoiding anti-
arrhythmic drug therapy make device implantation an at-
tractive option. In the present series, only one of the eight
patients experienced a late recurrence after initially success-
ful ablation with follow-up ranging from 2 to 46 months.
Catheter ablation can be a lifesaving therapy for patients
with incessant VT. Brugada et al. (18) have shown that
epicardial ablation can be a life saving option when endocardial
ablation fails or cannot be attempted. Due to the technical
challenges of catheter ablation for VT and the relatively low
incidence of this problem, this therapy will largely remain in
experienced centers. As shown by Brugada et al. (18), appli-
cation of Dr. Sosa’s pioneering work in percutaneous mapping
and ablation from within the pericardial space provides an impor-
tant option for controlling this potentially fatal arrhythmia.
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